A candidate malaria vaccine developed by GlaxoSmithKline Plc has shown efficacy in a Phase 3 trial in infants in Africa. But the results were less robust than expected. Researchers involved in the project said they will continue to analyse the data to clarify how the vaccine might play a role in overall malaria prevention.
